Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2010, Article ID 345098, 6 pages
http://dx.doi.org/10.1155/2010/345098
Review Article

Role of PPAR and Its Agonist in Renal Diseases

1Department of Medical Research, Tzu Chi General Hospital and Department of Pediatrics, Tzu Chi University, Hualien 970, Taiwan
2Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan
3Graduate Institute of Clinical Medicine, Taipei Medical University and Department of Internal Medicine, Taipei Medical University Hospital, Taipei 110, Taiwan
4Graduate Institute of Pharmacology and Toxicology, Tzu Chi University, 701 Chung Yang Road, Section 3, Hualien 970, Taiwan

Received 17 June 2010; Accepted 17 October 2010

Academic Editor: Béatrice Desvergne

Copyright © 2010 Ching-Feng Cheng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. P. Berger, T. E. Akiyama, and P. T. Meinke, “PPARs: therapeutic targets for metabolic disease,” Trends in Pharmacological Sciences, vol. 26, no. 5, pp. 244–251, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. J. C. Fruchart, B. Staels, and P. Duriez, “The role of fibric acids in atherosclerosis,” Current Atherosclerosis Reports, vol. 3, no. 1, pp. 83–92, 2001. View at Google Scholar · View at Scopus
  3. L. Fajas, M.-B. Debril, and J. Auwerx, “Peroxisome proliferator-activated receptor-γ: from adipogenesis to carcinogenesis,” Journal of Molecular Endocrinology, vol. 27, no. 1, pp. 1–9, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Mukherjee, L. Jow, D. Noonan, and D. P. McDonnell, “Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators,” Journal of Steroid Biochemistry and Molecular Biology, vol. 51, no. 3-4, pp. 157–166, 1994. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Guan, Y. Zhang, L. Davis, and M. D. Breyer, “Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans,” American Journal of Physiology, vol. 273, no. 6, part 2, pp. F1013–F1022, 1997. View at Google Scholar · View at Scopus
  6. X. Z. Ruan, J. F. Moorhead, R. Fernando, D. C. Wheeler, S. H. Powis, and Z. Varghese, “PPAR agonists protect mesangial cells from interleukin 1β-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway,” Journal of the American Society of Nephrology, vol. 14, no. 3, pp. 593–600, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Guan, Y. Zhang, A. Schneider, L. Davis, R. M. Breyer, and M. D. Breyer, “Peroxisome proliferator-activated receptor-γ activity is associated with renal microvasculature,” American Journal of Physiology, vol. 281, no. 6, pp. F1036–F1046, 2001. View at Google Scholar · View at Scopus
  8. E. Letavernier, J. Perez, E. Joye et al., “Peroxisome proliferator-activated receptor β/δ exerts a strong protection from ischemic acute renal failure,” Journal of the American Society of Nephrology, vol. 16, no. 8, pp. 2395–2402, 2005. View at Publisher · View at Google Scholar
  9. B. H. Chung, S. W. Lim, K. O. Ahn et al., “Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and non-diabetic renal diseases,” Nephrology, vol. 10, supplement 2, pp. S40–S43, 2005. View at Publisher · View at Google Scholar
  10. S. Cuzzocrea, “Peroxisome proliferator-activated receptors gamma ligands and ischemia and reperfusion injury,” Vascular Pharmacology, vol. 41, no. 6, pp. 187–195, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Portilla, G. Dai, J. M. Peters, F. J. Gonzalez, M. D. Crew, and A. D. Proia, “Etomoxir-induced PPARα-modulated enzymes protect during acute renal failure,” American Journal of Physiology, vol. 278, no. 4, pp. F667–F675, 2000. View at Google Scholar · View at Scopus
  12. S. Li, R. Bhatt, J. Megyesi, N. Gokden, S. V. Shah, and D. Portilla, “PPAR-α ligand ameliorates acute renal failure by reducing cisplatin-induced increased expression of renal endonuclease G,” American Journal of Physiology, vol. 287, no. 5, pp. F990–F998, 2004. View at Publisher · View at Google Scholar
  13. B. Staels and J.-C. Fruchart, “Therapeutic roles of peroxisome proliferator-activated receptor agonists,” Diabetes, vol. 54, no. 8, pp. 2460–2470, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. Z. Israelian-Konaraki and P. D. Reaven, “Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications,” Cardiology, vol. 103, no. 1, pp. 1–9, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. A. S. Wierzbicki, “Fibrates: no ACCORD on their use in the treatment of dyslipidaemia,” Current Opinion in Lipidology, vol. 21, no. 4, pp. 352–358, 2010. View at Publisher · View at Google Scholar
  16. F. Ismail-Beigi, T. Craven, M. A. Banerji et al., “Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial,” The Lancet, vol. 376, no. 9739, pp. 419–430, 2010. View at Publisher · View at Google Scholar
  17. D. de Zeeuw, H.-H. Parving, and R. H. Henning, “Microalbuminuria as an early marker for cardiovascular disease,” Journal of the American Society of Nephrology, vol. 17, no. 8, pp. 2100–2105, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Czekalski, “Microalbuminuria as a reversible marker of kidney and vascular damage,” Nefrologia i Dializoterapia Polska, vol. 10, no. 4, pp. 166–168, 2006. View at Google Scholar
  19. G. Cerasola, S. Cottone, and G. Mulè, “The progressive pathway of microalbuminuria: from early marker of renal damage to strong cardiovascular risk predictor,” Journal of Hypertension. In press. View at Publisher · View at Google Scholar
  20. D. Portilla, “Energy metabolism and cytotoxicity,” Seminars in Nephrology, vol. 23, no. 5, pp. 432–438, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. F. Beck, S. Plummer, P. V. Senior, S. Byrne, S. Green, and W. J. Brammar, “The ontogeny of peroxisome-proliferator-activated receptor gene expression in the mouse and rat,” Proceedings of the Royal Society B, vol. 247, no. 1319, pp. 83–87, 1992. View at Google Scholar · View at Scopus
  22. D. Portilla, G. Dai, J. M. Peters, F. J. Gonzalez, M. D. Crew, and A. D. Proia, “Etomoxir-induced PPARα-modulated enzymes protect during acute renal failure,” American Journal of Physiology, vol. 278, no. 4, pp. F667–F675, 2000. View at Google Scholar · View at Scopus
  23. F. Ouali, F. Djouadi, C. Merlet-Bénichou, and J. Bastin, “Dietary lipids regulate β-oxidation enzyme gene expression in the developing rat kidney,” American Journal of Physiology, vol. 275, no. 5, pp. F777–F784, 1998. View at Google Scholar · View at Scopus
  24. M. C. Sugden, K. Bulmer, G. F. Gibbons, and M. J. Holness, “Role of peroxisome proliferator-activated receptor-α in the mechanism underlying changes in renal pyruvate dehydrogenase kinase isoform 4 protein expression in starvation and after refeeding,” Archives of Biochemistry and Biophysics, vol. 395, no. 2, pp. 246–252, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. L. F. Fried, T. J. Orchard, and B. L. Kasiske, “Effect of lipid reduction on the progression of renal disease: a meta-analysis,” Kidney International, vol. 59, no. 1, pp. 260–269, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. M. Smolders, A. E. van Eeden, C. D. A. Stehouwer, R. N. M. Weijers, E. H. Slaats, and J. Silberbusch, “Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus?” European Journal of Clinical Investigation, vol. 27, no. 12, pp. 997–1002, 1997. View at Google Scholar · View at Scopus
  27. A. Keech, R. J. Simes, P. Barter et al., “Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial,” The Lancet, vol. 366, no. 9500, pp. 1849–1861, 2005. View at Google Scholar
  28. C. W. Park, Y. Zhang, X. F. Fan et al., “A PPARa agonist improves diabetic nephropathy in db/db mice,” Journal of the American Society of Nephrology, vol. 14, p. 393A, 2003. View at Google Scholar
  29. C. W. Park, Y. Zhang, X. Zhang et al., “PPARα agonist fenofibrate improves diabetic nephropathy in db/db mic,” Kidney International, vol. 69, no. 9, pp. 1511–1517, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. W. A. Wilmer, C. L. Dixon, C. Hebert, L. Lu, and B. H. Rovin, “PPAR-α ligands inhibit H2O2-mediated activation of transforming growth factor-β1 in human mesangial cells,” Antioxidants & Redox Signaling, vol. 4, no. 6, pp. 877–884, 2002. View at Google Scholar · View at Scopus
  31. X. Hou, Y. H. Shen, C. Li et al., “PPARα agonist fenofibrate protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress and MAPK activity,” Biochemical and Biophysical Research Communications, vol. 394, no. 3, pp. 653–659, 2010. View at Publisher · View at Google Scholar
  32. L. Li, N. Emmett, D. Mann, and X. Zhao, “Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy,” Experimental Biology and Medicine, vol. 235, no. 3, pp. 383–391, 2010. View at Publisher · View at Google Scholar
  33. H.-H. Chen, T.-W. Chen, and H. Lin, “Prostacyclin-induced peroxisome proliferator-activated receptor-α translocation attenuates NF-κB and TNF-α activation after renal ischemia-reperfusion injury,” American Journal of Physiology, vol. 297, no. 4, pp. F1109–F1118, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Liao, Z. Soltani, P. Ebenezer et al., “Tesaglitazar, a dual peroxisome proliferator-activated receptor agonist (PPARα/γ), improves metabolic abnormalities and reduces renal injury in obese Zucker rats,” Nephron Experimental Nephrology, vol. 114, no. 2, pp. e61–e68, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. A. C. Calkin, S. Giunti, K. A. Jandeleit-Dahm, T. J. Allen, M. E. Cooper, and M. C. Thomas, “PPAR-α and -γ agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse,” Nephrology Dialysis Transplantation, vol. 21, no. 9, pp. 2399–2405, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. E. Robinson and D. J. Grieve, “Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease,” Pharmacology & Therapeutics, vol. 122, no. 3, pp. 246–263, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Seiler, T. M. Suter, and O. M. Hess, “Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate,” Journal of the American College of Cardiology, vol. 26, no. 7, pp. 1615–1622, 1995. View at Publisher · View at Google Scholar · View at Scopus
  38. A. J. Gilde, K. A.J.M. van der Lee, P. H.M. Willemsen et al., “Peroxisome proliferator-activated receptor (PPAR) α and PPARβ/δ, but not PPARγ, modulate the expression of genes involved in cardiac lipid metabolism,” Circulation Research, vol. 92, no. 5, pp. 518–524, 2003. View at Publisher · View at Google Scholar
  39. A. Zambon, P. Gervois, P. Pauletto, J.-C. Fruchart, and B. Staels, “Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-α activators: clinical and experimental evidence,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 5, pp. 977–986, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. R. Thadhani, M. Pascual, and J. V. Bonventre, “Acute renal failure,” The New England Journal of Medicine, vol. 334, no. 22, pp. 1448–1460, 1996. View at Google Scholar · View at Scopus
  41. F. J. Lopez-Hernandez and J. M. Lopez-Novoa, “Potential utility of PPARα activation in the prevention of ischemic and drug-induced acute renal damage,” Kidney International, vol. 76, no. 10, pp. 1022–1024, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Sivarajah, P. K. Chatterjee, Y. Hattori et al., “Agonists of peroxisome-proliferator activated receptor-α (clofibrate and WY14643) reduce renal ischemia/reperfusion injury in the rat,” Medical Science Monitor, vol. 8, no. 12, pp. BR532–BR539, 2002. View at Google Scholar · View at Scopus
  43. S. Li, K. K. Nagothu, V. Desai et al., “Transgenic expression of proximal tubule peroxisome proliferator-activated receptor-α in mice confers protection during acute kidney injury,” Kidney International, vol. 76, no. 10, pp. 1049–1062, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. B. Pourcet, I. Pineda-Torra, B. Derudas, B. Staels, and C. Glineur, “SUMOylation of human peroxisome proliferator-activated receptor α inhibits its trans-activity through the recruitment of the nuclear corepressor NCoR,” Journal of Biological Chemistry, vol. 285, no. 9, pp. 5983–5992, 2010. View at Publisher · View at Google Scholar
  45. G. Dogra, A. Irish, D. Chan, and G. Watts, “A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD,” American Journal of Kidney Diseases, vol. 49, no. 6, pp. 776–785, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. D. A. Sica, “Fibrate therapy and renal function,” Current Atherosclerosis Reports, vol. 11, no. 5, pp. 338–342, 2009. View at Publisher · View at Google Scholar · View at Scopus